Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2022 | Gene expression assays to identify patients with breast cancer for neoadjuvant treatment

Gaia Griguolo • 3 May 2022
ESMO Breast 2022
Breast Cancer

Gaia Griguolo, MD, University of Padova, Padova, Italy, talks on utilizing gene expression assays to aid in identifying subgroups of patients with HR-positive/HER2-negative breast cancer who have superior response rates to particular agents. Such assays could help to identify candidates for treatment in the neoadjuvant setting. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.

More from Gaia Griguolo

2:09
HRD, RB-loss gene sig, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early BC
Gaia Griguolo • 7 Dec 2022
0:53
The latest news on the management of breast cancer patients with brain metastases
Gaia Griguolo • 7 Dec 2022
1:35
Gene expression profiling of breast cancer brain mets shows enrichment for non-luminal subtypes
Gaia Griguolo • 7 Dec 2022
2:05
PerELISA: overexpression of 13 genes associated with endocrine sensitivity in HR+/HER2+ BC
Gaia Griguolo • 3 May 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals